Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options

by Carmen Portenkirchner, Peter Kienle, Karoline Horisberger
Published 2021-04-01

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management

by Muhammet Gürdoğan, Kenan Yalta
Published 2020-07-01

Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis

by Yunwei LIU, Yanxin CHEN, Zhimin ZENG, Anwen LIU
Published 2021-09-01

High‐dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors––A nationwide register‐based cohort study

by Signe Sørup, Bianka Darvalics, Leo Russo, Dina Oksen, Francois‐Xavier Lamy, Patrice Verpillat, Khalil AA, Sørensen HT, Deirdre Cronin‐Fenton
Published 2021-07-01

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis

by Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Yue Li, Lian Duan, Xiaoyan Si, Li Zhang, Xiaowei Liu, Mengzhao Wang, Juhong Shi, Li Zhang
Published 2020-01-01

Mechanism and Strategy of Combination Immunotherapy in Integrated Tumor Therapy

by WANG Zhigao, FANG Qiqi, GAO Fei, LI Qingxia
Published 2020-11-01

Cryoablation and immunotherapy: an overview of evidence on its synergy

by B. M. Aarts, E. G. Klompenhouwer, S. L. Rice, F. Imani, T. Baetens, A. Bex, S. Horenblas, M. Kok, J. B. A. G. Haanen, R. G. H. Beets-Tan, F. M. Gómez
Published 2019-05-01

Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?

by Nagio Takigawa, Nobuaki Ochi, Nozomu Nakagawa, Yasunari Nagasaki, Masataka Taoka, Naruhiko Ichiyama, Ayaka Mimura, Hidekazu Nakanishi, Hiroyuki Kohara, Hiromichi Yamane
Published 2020-07-01

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

by Sehhoon Park, Je-Gun Joung, Yang Won Min, Jae-Yong Nam, Daeun Ryu, Dongryul Oh, Woong-Yang Park, Se-Hoon Lee, Yoon La Choi, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Published 2019-05-01

Clinical Diagnosis and Treatment Recommendations for Adverse Reaction in the Nervous System Related to Immunocheckpoint Inhibitor

by Jiayu SHI, Jingwen NIU, Dongchao SHEN, Yi LI, Mingsheng LIU, Ying TAN, Liying CUI, Yuzhou GUAN, Li ZHANG
Published 2019-10-01

Immunotherapy for Uterine Cervical Cancer

by Masahiro Kagabu, Takayuki Nagasawa, Daisuke Fukagawa, Hidetoshi Tomabechi, Saiya Sato, Tadahiro Shoji, Tsukasa Baba
Published 2019-09-01

Targeted Therapy with Sirolimus and Nivolumab in a Child with Refractory Multifocal Anaplastic Ependymoma

by Katia Perruccio, Angela Mastronuzzi, Marco Lupattelli, Francesco Arcioni, Ilaria Capolsini, Carla Cerri, Grazia M. I. Gurdo, Maria Speranza Massei, Elena Mastrodicasa, Maurizio Caniglia
Published 2021-05-01

The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development

by Sacdalan DB, Lucero JA
Published 2021-03-01

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

by Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Changhoon Yoo, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Jonggi Choi
Published 2020-07-01

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

by Yinghong Wang, Hamzah Abu-Sbeih, Emily Mao, Noman Ali, Faisal Shaukat Ali, Wei Qiao, Phillip Lum, Gottumukkala Raju, Gladis Shuttlesworth, John Stroehlein, Adi Diab
Published 2018-05-01

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

by Delong Liu
Published 2019-11-01

Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)

by Min Chul Choi, Yong-Man Kim, Jeong-Won Lee, Yong Jae Lee, Dong Hoon Suh, Sung Jong Lee, Taek Sang Lee, Maria Lee, Dong Choon Park, Min Kyu Kim, Jong-Min Lee, Seung-Hyuk Shim, Seob Jeon, Kyung Jin Min, Mi Kyung Kim, Bo Wook Kim, Jeong Yeol Park, Byoung-Gie Kim, Dae Yeon Kim, Moon-Hong Kim, Hyun-Soo Kim, Jung-Yun Lee
Published 2020-10-01

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions

by Masahiro Kagabu, Takayuki Nagasawa, Chie Sato, Yasuko Fukagawa, Hanae Kawamura, Hidetoshi Tomabechi, Shuji Takemoto, Tadahiro Shoji, Tsukasa Baba
Published 2020-03-01

Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

by Yoko Maegawa, Taigo Kato, Shinichiro Fukuhara, Hiroshi Kiuchi, Ryoichi Imamura, Motohide Uemura, Norio Nonomura, Kazutoshi Fujita
Published 2020-09-01

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events

by Peng Song, Hanping Wang, Xiaoyan Si, Xiaoxiao Guo, Yue Li, Jiaixin Zhou, Lian Duan, Li Zhang, Mengzhao Wang
Published 2020-08-01